Developing a Global Strategy for First Dengue Vaccine Deployment (IMAGE)

American Association for the Advancement of Science (AAAS)

Developing a Global Strategy for First Dengue Vaccine Deployment

Caption

An analysis performed by scientists studying the world's first marketed dengue virus vaccine (Dengvaxia) has identified the need for a better understanding of how it should be deployed on a global scale, perhaps in conjunction with a diagnostic tool to identify individuals most at risk of negative effects. This material relates to a paper that appeared in the Sept. 2, 2016 issue of <i>Science</i>, published by AAAS. The paper, by N.M. Ferguson at Johns Hopkins Bloomberg School of Public Health in Baltimore, MD, and colleagues was titled, "Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment."

Credit

Val Altounian / <i>Science</i> (2016)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.